These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33759847)

  • 1. Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.
    Rossow KM; Oshikoya KA; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    J Dev Behav Pediatr; 2021 Apr; 42(3):205-212. PubMed ID: 33759847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 genotype and adverse events to risperidone in children and adolescents.
    Oshikoya KA; Neely KM; Carroll RJ; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    Pediatr Res; 2019 Apr; 85(5):602-606. PubMed ID: 30661084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism.
    Shilbayeh SAR; Adeen IS; Alhazmi AS; Ibrahim SF; Al Enazi FAR; Ghanem EH; Binduraihem AM
    Biochem Genet; 2024 Aug; 62(4):2907-2932. PubMed ID: 38041757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism.
    Shilbayeh SAR; Adeen IS; Alhazmi AS; Aljurayb H; Altokhais RS; Alhowaish N; Aldilaijan KE; Kamal M; Alnakhli AM
    Eur J Clin Pharmacol; 2024 Jun; 80(6):869-890. PubMed ID: 38421437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents.
    Kanu AA; Johnston MM; Poweleit EA; Vaughn SE; Strawn JR; Ramsey LB
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):34-41. PubMed ID: 38377522
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
    de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
    J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
    Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
    Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
    Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
    Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
    Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
    J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron.
    Black K; Brenn BR; Gaedigk A; Wanderer JP; Van Driest SL
    Clin Transl Sci; 2023 Feb; 16(2):269-278. PubMed ID: 36350309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
    Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
    J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.